Tofacitinib Extended Release 11 & TACOTINIB ER 11mg:View Uses,benefits,Dosage,Precuations

TACOTINIB ER 11

Tofacitinib Extended Release 11 mg

TACOTINIB ER 11 combination of Tofacitinib Extended Release 11 mg, also known as TACOTINIB ER 11, is an oral medication belonging to the class of Janus kinase (JAK) inhibitors. This extended-release formulation is prescribed for the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis in adult patients who have not responded adequately to other therapies. In this article, we explore the uses, benefits, and mechanism of action of Tofacitinib Extended Release 11 mg in detail.

Understanding Tofacitinib Extended Release 11 mg:

Tofacitinib Extended Release 11 mg is designed to provide sustained release of the active ingredient, tofacitinib, over an extended period, allowing for once-daily dosing. Tofacitinib inhibits Janus kinases (JAKs), which are enzymes involved in signaling pathways that regulate the immune response. By blocking these pathways, Tofacitinib helps to reduce inflammation and alleviate symptoms associated with autoimmune diseases.

Key Benefits of Tofacitinib Extended Release 11 mg:

• Convenience of Once-Daily Dosing: Tofacitinib Extended Release 11 mg offers the convenience of once-daily dosing, allowing patients to maintain consistent drug levels in their system without the need for multiple daily administrations.
• Improved Treatment Adherence: The extended-release formulation of Tofacitinib may improve treatment adherence by reducing the frequency of dosing, leading to better long-term outcomes for patients.
• Efficacy in Multiple Indications: Tofacitinib Extended Release 11 mg has demonstrated efficacy in the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, providing a versatile treatment option for patients with different autoimmune conditions.

Clinical Uses of Tofacitinib Extended Release 11 mg:

• Rheumatoid Arthritis: Tofacitinib Extended Release 11 mg is indicated for the treatment of moderate to severe rheumatoid arthritis in adults who have had an inadequate response or intolerance to methotrexate.
• Psoriatic Arthritis: It is also approved for the treatment of active psoriatic arthritis in adults, either as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs (DMARDs).
• Ulcerative Colitis: Tofacitinib Extended Release 11 mg is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients who have not responded adequately to conventional therapy.

Dosage and Administration:

• Starting Dosage: The recommended starting dosage of Tofacitinib Extended Release 11 mg for rheumatoid arthritis and psoriatic arthritis is 11 mg taken orally once daily.
• Titration: Depending on the patient's response to treatment, the dosage may be titrated up to 22 mg once daily or down to 5 mg once daily.
• Ulcerative Colitis: For ulcerative colitis, the recommended dosage is 11 mg taken orally once daily.

Safety Profile and Precautions:

• Infections: Patients taking Tofacitinib Extended Release 11 mg may be at increased risk of infections, including serious and sometimes fatal infections. It is essential to monitor for signs of infection and to take appropriate precautions.
• Malignancy: There have been reports of an increased risk of malignancy, including lymphoma and skin cancer, in patients treated with Tofacitinib. Regular monitoring is recommended.
• Thrombosis: Tofacitinib may increase the risk of thrombosis, particularly in patients with risk factors such as hypertension or a history of cardiovascular disease.

Conclusion:

Tofacitinib Extended Release 11 mg, marketed as TACOTINIB ER 11, offers a promising treatment option for patients with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. By providing sustained release of tofacitinib over an extended period, this formulation allows for once-daily dosing, improving treatment adherence and convenience for patients. However, it is crucial to use Tofacitinib Extended Release 11 mg cautiously, under the guidance of a healthcare professional, to ensure optimal therapeutic outcomes and minimize the risk of adverse effects.Steris Healthcare Pvt Ltd, founded by a group of expert professionals in the pharmaceutical industry in February 2018, operates as Sterispharma. This company, which is based in Navi Mumbai, holds certifications from WHO, GMP, and ISO. Its commitment is to provide high-quality drugs at affordable prices to its customers throughout India, following the rigorous guidelines set by the WHO. Steris offers the convenience of an online pharmacy where customers can easily buy medicines and enjoy the benefit of home delivery. At Steris, the mission is to supply a wide array of healthcare products designed to meet the varied needs of the medical community. Whether it is advanced treatments, medications for rare conditions, or basic health necessities, Sterispharma strives to serve the healthcare industry’s broad demands. The extensive product lineup from Steris includes treatments for various health areas such as Cardiology, Asthma, Respiratory issues, Nasal conditions, Diabetes, Endocrinology, Gastroenterology, Orthopedics, Anti-infectives/antibiotics, General Medicine, Urology, Neurology, Nephrology, Oncology, Gynecology, Pediatrics, Dental care, and Dermatology.

For further information: 

EMAIL:  info@sterispharma.com  / contact@sterispharma.com   

CALL/WHATSAPP: 7877551268, 7849827488

BUY NOW